Your browser doesn't support javascript.
loading
Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer.
Kasikova, Lenka; Rakova, Jana; Hensler, Michal; Lanickova, Tereza; Tomankova, Jana; Pasulka, Josef; Drozenova, Jana; Mojzisova, Katerina; Fialova, Anna; Vosahlikova, Sarka; Laco, Jan; Ryska, Ales; Dundr, Pavel; Kocian, Roman; Brtnicky, Tomas; Skapa, Petr; Capkova, Linda; Kovar, Marek; Prochazka, Jan; Praznovec, Ivan; Koblizek, Vladimir; Taskova, Alice; Tanaka, Hisashi; Lischke, Robert; Mendez, Fernando Casas; Vachtenheim, Jiri; Heinzelmann-Schwarz, Viola; Jacob, Francis; McNeish, Iain A; Halaska, Michal J; Rob, Lukas; Cibula, David; Orsulic, Sandra; Galluzzi, Lorenzo; Spisek, Radek; Fucikova, Jitka.
Afiliação
  • Kasikova L; Sotio Biotech a.s., Prague, Czech Republic.
  • Rakova J; Sotio Biotech a.s., Prague, Czech Republic.
  • Hensler M; Sotio Biotech a.s., Prague, Czech Republic.
  • Lanickova T; Sotio Biotech a.s., Prague, Czech Republic.
  • Tomankova J; Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
  • Pasulka J; Sotio Biotech a.s., Prague, Czech Republic.
  • Drozenova J; Sotio Biotech a.s., Prague, Czech Republic.
  • Mojzisova K; Department of Pathology, 3rd Faculty of Medicine and University Hospital Kralovske Vinohrady, Prague, Czech Republic.
  • Fialova A; Sotio Biotech a.s., Prague, Czech Republic.
  • Vosahlikova S; Sotio Biotech a.s., Prague, Czech Republic.
  • Laco J; Sotio Biotech a.s., Prague, Czech Republic.
  • Ryska A; The Fingerland Department of Pathology, Charles University, Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic.
  • Dundr P; The Fingerland Department of Pathology, Charles University, Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic.
  • Kocian R; Department of Pathology, 1st Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
  • Brtnicky T; Department of Gynaecology, Obstetrics and Neonatology, General University Hospital in Prague, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.
  • Skapa P; Department of Gynecology and Obstetrics, 1st Faculty of Medicine, Charles University, University Hospital Bulovka, Prague, Czech Republic.
  • Capkova L; Department of Pathology and Molecular Medicine, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
  • Kovar M; Department of Pathology and Molecular Medicine, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
  • Prochazka J; Laboratory of Tumor Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic.
  • Praznovec I; Czech Center for Phenogenomics, Institute of Molecular Genetics of the Czech Academy of Sciences, Vestec, Czech Republic.
  • Koblizek V; Department of Gynecology and Obstetrics, Charles University, Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic.
  • Taskova A; Department of Pneumology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic.
  • Tanaka H; Department of Thoracic Surgery, Charles University, 3rd Faculty of Medicine and Thomayer University Hospital, Prague, Czech Republic.
  • Lischke R; Departments of Surgery and Biomedical Sciences, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, West Hollywood, CA, USA.
  • Mendez FC; 3rd Department of Surgery, First Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
  • Vachtenheim J; Oncology and Pneumology Department, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
  • Heinzelmann-Schwarz V; 3rd Department of Surgery, First Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
  • Jacob F; Ovarian Cancer Research, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland.
  • McNeish IA; Ovarian Cancer Research, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Halaska MJ; Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London, UK.
  • Rob L; Department of Gynecology and Obstetrics, Charles University, 3rd Faculty of Medicine and University Hospital Kralovske Vinohrady, Prague, Czech Republic.
  • Cibula D; Department of Gynecology and Obstetrics, Charles University, 3rd Faculty of Medicine and University Hospital Kralovske Vinohrady, Prague, Czech Republic.
  • Orsulic S; Department of Gynaecology, Obstetrics and Neonatology, General University Hospital in Prague, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.
  • Galluzzi L; Department of Obstetrics and Gynecology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
  • Spisek R; Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.
  • Fucikova J; Sandra and Edward Meyer Cancer Center, New York, NY, USA.
Nat Commun ; 15(1): 2528, 2024 Mar 21.
Article em En | MEDLINE | ID: mdl-38514660
ABSTRACT
Intratumoral tertiary lymphoid structures (TLSs) have been associated with improved outcome in various cohorts of patients with cancer, reflecting their contribution to the development of tumor-targeting immunity. Here, we demonstrate that high-grade serous ovarian carcinoma (HGSOC) contains distinct immune aggregates with varying degrees of organization and maturation. Specifically, mature TLSs (mTLS) as forming only in 16% of HGSOCs with relatively elevated tumor mutational burden (TMB) are associated with an increased intratumoral density of CD8+ effector T (TEFF) cells and TIM3+PD1+, hence poorly immune checkpoint inhibitor (ICI)-sensitive, CD8+ T cells. Conversely, CD8+ T cells from immunologically hot tumors like non-small cell lung carcinoma (NSCLC) are enriched in ICI-responsive TCF1+ PD1+ T cells. Spatial B-cell profiling identifies patterns of in situ maturation and differentiation associated with mTLSs. Moreover, B-cell depletion promotes signs of a dysfunctional CD8+ T cell compartment among tumor-infiltrating lymphocytes from freshly isolated HGSOC and NSCLC biopsies. Taken together, our data demonstrate that - at odds with NSCLC - HGSOC is associated with a low density of follicular helper T cells and thus develops a limited number of mTLS that might be insufficient to preserve a ICI-sensitive TCF1+PD1+ CD8+ T cell phenotype. These findings point to key quantitative and qualitative differences between mTLSs in ICI-responsive vs ICI-irresponsive neoplasms that may guide the development of alternative immunotherapies for patients with HGSOC.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Carcinoma Pulmonar de Células não Pequenas / Estruturas Linfoides Terciárias / Neoplasias Pulmonares Limite: Female / Humans Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: República Tcheca

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Carcinoma Pulmonar de Células não Pequenas / Estruturas Linfoides Terciárias / Neoplasias Pulmonares Limite: Female / Humans Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: República Tcheca